Xinli Song
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xinli Song has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
Jian Xu
School of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang, 550025, China
2 shared publicationsShiyun Wang
School of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang, 550025, China
2 shared publicationsYanli Cai
School of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang, 550025, China
2 shared publications- Changfu Yang
College of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang 550025, China
1 shared publication Chenghao Tao
College of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou 310053, China
1 shared publicationDaobin Yang
The Second Affiliated Hospital of Guizhou, University of Traditional Chinese Medicine, Guiyang, 550025, China
1 shared publication
Latest Publications
- Open Access
- 12 August 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 16 (37) , 40397-40414
Optimization of Xiaoer Lingyin granule formulation using single-factor and response surface methodology
The study aimed to develop and optimize Xiaoer Lingyin granules (XLGs), a pediatric Chinese medicine formulation for acute pharyngitis, by integrating single-factor experiments, multi-index quality evaluation, and response surface methodology (RSM).
- 12 August 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 16 (37) , 40397-40414
Open AccessOptimization of Xiaoer Lingyin granule formulation using single-factor and response surface methodology
The study aimed to develop and optimize Xiaoer Lingyin granules (XLGs), a pediatric Chinese medicine formulation for acute pharyngitis, by integrating single-factor experiments, multi-index quality evaluation, and response surface methodology (RSM).
- 9 July 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (13) , 20739-20756
Acupoint-administered sinapine thiocyanate-loaded dissolvable microneedles for bronchial asthma: dose–response relationship and PI3K/AKT signaling pathway-based mechanism
Bronchial asthma (BA) is a chronic inflammatory airway disease for which conventional drug delivery routes show limited therapeutic efficacy. Herbal acupoint application offers targeted therapeutic benefits by combining pharmacological effects with specific acupoint stimulation; however, conventional patches are limited by poor sustained release and low patient compliance. Sinapine thiocyanate, a natural alkaloid with anti-inflammatory properties, has potential for asthma treatment, yet its poor bioavailability hinders its therapeutic application. To address these gaps, we developed sinapine thiocyanate‑loaded dissolvable microneedles (ST‑DMN) using polyvinylpyrrolidone K30 (PVP‑K30) and chondroitin sulfate (CS) as matrix materials, and polyvinyl alcohol (PVA) as the backing layer, designed for acupoint administration to achieve sustained drug release and improve therapeutic outcomes. ST-DMN patches with drug loadings ranging from 0.25 to 2.0 mg/patch were prepared, and a dose-response relationship was established in a rat model of BA to identify the optimal drug loading. The results demonstrated that ST-DMN at 1.5 and 2.0 mg/patch significantly improved the behavioral status of asthmatic rats, increased immune organ coefficients, and reduced the expression of IgE, TNF-α, and IL-1β. Based on a comprehensive assessment of efficacy and safety, 1.5 mg/patch was selected as the optimal dose. Network pharmacology analysis predicted that the PI3K/AKT signaling pathway was highly relevant to the anti-asthmatic effects of sinapine thiocyanate. Subsequent validation in animal models confirmed that the optimal dose of ST-DMN effectively ameliorated lung tissue pathology and reduced inflammatory cell infiltration. Furthermore, ST-DMN treatment significantly decreased the expression levels of key inflammatory factors and inhibited PI3K and AKT phosphorylation. The current findings suggest that ST-DMN at 1.5 mg/patch exerts therapeutic effects against BA through acupoint administration, likely by modulating the PI3K/AKT signaling pathway and suppressing inflammatory responses.
- 9 July 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (13) , 20739-20756
Acupoint-administered sinapine thiocyanate-loaded dissolvable microneedles for bronchial asthma: dose–response relationship and PI3K/AKT signaling pathway-based mechanism
Bronchial asthma (BA) is a chronic inflammatory airway disease for which conventional drug delivery routes show limited therapeutic efficacy. Herbal acupoint application offers targeted therapeutic benefits by combining pharmacological effects with specific acupoint stimulation; however, conventional patches are limited by poor sustained release and low patient compliance. Sinapine thiocyanate, a natural alkaloid with anti-inflammatory properties, has potential for asthma treatment, yet its poor bioavailability hinders its therapeutic application. To address these gaps, we developed sinapine thiocyanate‑loaded dissolvable microneedles (ST‑DMN) using polyvinylpyrrolidone K30 (PVP‑K30) and chondroitin sulfate (CS) as matrix materials, and polyvinyl alcohol (PVA) as the backing layer, designed for acupoint administration to achieve sustained drug release and improve therapeutic outcomes. ST-DMN patches with drug loadings ranging from 0.25 to 2.0 mg/patch were prepared, and a dose-response relationship was established in a rat model of BA to identify the optimal drug loading. The results demonstrated that ST-DMN at 1.5 and 2.0 mg/patch significantly improved the behavioral status of asthmatic rats, increased immune organ coefficients, and reduced the expression of IgE, TNF-α, and IL-1β. Based on a comprehensive assessment of efficacy and safety, 1.5 mg/patch was selected as the optimal dose. Network pharmacology analysis predicted that the PI3K/AKT signaling pathway was highly relevant to the anti-asthmatic effects of sinapine thiocyanate. Subsequent validation in animal models confirmed that the optimal dose of ST-DMN effectively ameliorated lung tissue pathology and reduced inflammatory cell infiltration. Furthermore, ST-DMN treatment significantly decreased the expression levels of key inflammatory factors and inhibited PI3K and AKT phosphorylation. The current findings suggest that ST-DMN at 1.5 mg/patch exerts therapeutic effects against BA through acupoint administration, likely by modulating the PI3K/AKT signaling pathway and suppressing inflammatory responses.
- 12 May 2026
- Published by Springer Nature in Drug Delivery and Translational Research
Brucine-loaded hydrogel microneedles for sustained anti-inflammatory therapy in rheumatoid arthritis: programmable drug release and detachable design
This study aimed to develop a brucine (Bru) hydrogel-forming microneedle (Bru-HFM) delivery system that could achieve long-term, programmed drug release, through adjusting degree of cross-linking in polyvinyl alcohol (PVA)/carbomer 934P (CP) hydrogel. A one-way orthogonal experiment and a Franz diffusion cell were employed to optimize the preparation process. The resulting Bru-HFM exhibited favorable appearance, mechanical strength, and swelling properties. The drug release performance of the different drug-carrying sites of HFMs was compared. The results illustrated that in vivo drug release rate over 144 h was significantly higher in the needle body-carrying group (95.32%) than in the whole-microneedle (51.85%) and back-lining groups (57.39%). The amount of residue in the back-lining group was obvious, in line with expectations. The burst release rate of 78.81% could meet the high-dose demand during the acute phase of inflammation, whereas continuous release through the cross-linking network over 48-144 h achieved a total release rate of 95.32%. This covered the maintenance phase of chronic inflammation treatment, and the microneedles remained structurally intact at the end of drug release, permitting their detachable. The general pharmacodynamic evaluation results demonstrated that the pathological state of the ankle joints of rats with collagen-induced arthritis was significantly improved in the needle body-carrying group, which also exhibited significantly reduced serum levels of IL-6, IL-17, and TNF-α (all P < 0.05), indicating a significant therapeutic effect on rheumatoid arthritis. This study provides a new strategy and theoretical basis for designing HFMs for programmed drug release and inflammatory disease treatment.
- 12 May 2026
- Published by Springer Nature in Drug Delivery and Translational Research
Brucine-loaded hydrogel microneedles for sustained anti-inflammatory therapy in rheumatoid arthritis: programmable drug release and detachable design
This study aimed to develop a brucine (Bru) hydrogel-forming microneedle (Bru-HFM) delivery system that could achieve long-term, programmed drug release, through adjusting degree of cross-linking in polyvinyl alcohol (PVA)/carbomer 934P (CP) hydrogel. A one-way orthogonal experiment and a Franz diffusion cell were employed to optimize the preparation process. The resulting Bru-HFM exhibited favorable appearance, mechanical strength, and swelling properties. The drug release performance of the different drug-carrying sites of HFMs was compared. The results illustrated that in vivo drug release rate over 144 h was significantly higher in the needle body-carrying group (95.32%) than in the whole-microneedle (51.85%) and back-lining groups (57.39%). The amount of residue in the back-lining group was obvious, in line with expectations. The burst release rate of 78.81% could meet the high-dose demand during the acute phase of inflammation, whereas continuous release through the cross-linking network over 48-144 h achieved a total release rate of 95.32%. This covered the maintenance phase of chronic inflammation treatment, and the microneedles remained structurally intact at the end of drug release, permitting their detachable. The general pharmacodynamic evaluation results demonstrated that the pathological state of the ankle joints of rats with collagen-induced arthritis was significantly improved in the needle body-carrying group, which also exhibited significantly reduced serum levels of IL-6, IL-17, and TNF-α (all P < 0.05), indicating a significant therapeutic effect on rheumatoid arthritis. This study provides a new strategy and theoretical basis for designing HFMs for programmed drug release and inflammatory disease treatment.
- 5 May 2024
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 15 (2) , 523-533
Enhanced efficacy of brucine dissolving-microneedles as a targeted delivery system in rheumatoid arthritis treatment: a comprehensive pharmacokinetic-pharmacodynamic analysis
Our previous studies have shown the therapeutic efficacy of brucine dissolving-microneedles (Bru-DMNs) in treating rheumatoid arthritis (RA). Bru delivered via the DMNs can bypass some of the issues related to oral and systemic delivery, including extensive enzymatic activity, liver metabolism and in the case of systemic delivery via hypodermic needles, pain resulting from injections and needle stick injury. However, the underlying mechanism of Bru-DMNs against RA has not been investigated in depth at the pharmacokinetic-pharmacodynamic (PK-PD) level. In this study, a microdialysis-based method combined with ultra-performance liquid chromatography-tandem mass spectrometry was developed for the simultaneous and continuous sampling and quantitative analysis of blood and joint cavities in fully awake RA rats. The acquired data were analyzed by the PK-PD analysis method. Bru delivered via microneedles showed enhanced distribution and prolonged retention in the joint cavity compared to its administration in blood. The correlation between the effect of Bru and its concentration at the action site was indirect. In this study, we explored the mechanism of Bru-DMNs against RA and established a visualization method to express the PK-PD relationship of Bru-DMNs against RA. This study provides insights into the mechanism of action of drugs with potential side effects administered transdermally for RA treatment. Graphical Abstract
- 5 May 2024
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 15 (2) , 523-533
Enhanced efficacy of brucine dissolving-microneedles as a targeted delivery system in rheumatoid arthritis treatment: a comprehensive pharmacokinetic-pharmacodynamic analysis
Our previous studies have shown the therapeutic efficacy of brucine dissolving-microneedles (Bru-DMNs) in treating rheumatoid arthritis (RA). Bru delivered via the DMNs can bypass some of the issues related to oral and systemic delivery, including extensive enzymatic activity, liver metabolism and in the case of systemic delivery via hypodermic needles, pain resulting from injections and needle stick injury. However, the underlying mechanism of Bru-DMNs against RA has not been investigated in depth at the pharmacokinetic-pharmacodynamic (PK-PD) level. In this study, a microdialysis-based method combined with ultra-performance liquid chromatography-tandem mass spectrometry was developed for the simultaneous and continuous sampling and quantitative analysis of blood and joint cavities in fully awake RA rats. The acquired data were analyzed by the PK-PD analysis method. Bru delivered via microneedles showed enhanced distribution and prolonged retention in the joint cavity compared to its administration in blood. The correlation between the effect of Bru and its concentration at the action site was indirect. In this study, we explored the mechanism of Bru-DMNs against RA and established a visualization method to express the PK-PD relationship of Bru-DMNs against RA. This study provides insights into the mechanism of action of drugs with potential side effects administered transdermally for RA treatment. Graphical Abstract